Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals (IONS) — Form 4: EVP and Chief Human Resources Officer Shannon L. Devers exercised options for 6,000 shares at $48.51 on 10/15/2025, then sold 6,000 shares the same day at a weighted average price of $72.9423 pursuant to a Rule 10b5-1 trading plan adopted on September 3, 2024. Also on 10/15/2025, 2,820 shares were acquired upon RSU vesting at no cost, and on 10/16/2025, 1,263 shares were sold at $73.6213 to cover tax withholding.
Following these transactions, Devers directly owned 17,494 shares of common stock. RSUs vest in four equal annual installments; each RSU represents a right to one share or its cash equivalent. The stock option exercised was originally granted on 04/05/2021 and expires on 04/04/2027.
Ionis Pharmaceuticals (IONS) disclosed insider transactions by EVP, Corp and Development Ops Brian Birchler. On 10/14/2025 and 10/15/2025, he exercised non-qualified stock options at $53.77 for 11,475 and 12,425 shares (codes M) and sold the same amounts at weighted average prices of $72.0339 and $72.2252 (codes S) pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. After these trades, he directly owned 56,826 shares.
Officer sale under 10b5-1 plan reduced direct holdings. An executive, Eric Swayze, reported the sale of 6,849 shares of Ionis Pharmaceuticals common stock on 10/06/2025 at a weighted-average price of $69.02. The filing states these sales were executed pursuant to a Rule 10b5-1 trading plan adopted on 08/14/2024, meaning they were pre-arranged instructions rather than discretionary trades.
After the transactions, the reporting person beneficially owns 30,453 shares directly and an additional 184 shares indirectly through a family member. The filer offers to provide detailed per-trade price information to the company, shareholders, or the SEC on request.
Insider transactions by Patrick R. O'Neil, EVP, CLO & General Counsel at Ionis Pharmaceuticals (IONS). On 10/06/2025 the reporting person exercised 10,200 non‑qualified stock options with an exercise price of $52.87 and immediately sold those shares under a Rule 10b5‑1 plan. The Form 4 reports two separate block sales that day: 10,200 shares sold at a weighted average price of $69.8872 and 3,241 shares sold at a weighted average price of $69.2651, reflecting multiple executions within disclosed price ranges.
Following these transactions the reporting person’s beneficial ownership of common stock declined from 67,330 shares to 53,889, and the number of options/derivative securities held after the activity is reported as 17,000 exercisable into common stock. The sales were made pursuant to a 10b5‑1 trading plan adopted on 05/02/2025, and the filer offers to provide transaction‑level price details on request.
Brett P. Monia, Chief Executive Officer and Director of Ionis Pharmaceuticals (IONS), reported a sale of common stock under a pre-established Rule 10b5-1 trading plan. The report shows 437 shares were sold on 10/06/2025 at $69.2637 per share, leaving the reporting person with 179,572 shares beneficially owned after the transaction. The filing notes the 10b5-1 plan was adopted on 08/13/2024 and the Form 4 was signed via attorney-in-fact on 10/08/2025. The transaction is described as executed pursuant to the trading plan.
Insider sale under 10b5-1 plan. An officer of Ionis Pharmaceuticals (IONS), Joseph T. Baroldi, sold 1,625 shares of common stock on 10/06/2025 at a weighted-average price of $69.3693 per share under a Rule 10b5-1 trading plan adopted on 05/02/2025. After the reported sale, Mr. Baroldi directly beneficially owns 30,301 shares and indirectly owns 3,071 shares through his spouse. The filer notes the sale occurred in multiple transactions at prices ranging from $69.36 to $69.41 and offers to provide a price-by-price breakdown on request.
Insider notice to sell common stock: A Form 144 filing shows proposed sale of 437 shares of common stock on 10/06/2025 via Stifel Nicolaus & Company on Nasdaq with an aggregate market value of $30,268.00. The shares were acquired under an Employee Stock Purchase Plan on 09/03/2024 and paid in cash. The filer represents no undisclosed material adverse information and the filing includes prior sales by the same person totaling 208,648 shares across dates in 2025 with gross proceeds shown (largest single prior sale: $12,228,840.00 on 09/03/2025). The notice states standard Rule 144 and Rule 10b5-1 remarks and signature attestation.
Form 144 notice shows a proposed sale of 1,625 common shares by an insider who acquired them as restricted stock units on 04/15/2025. The shares are to be sold through Stifel Nicolaus & Company on 10/06/2025 with an aggregate market value of $112,725.00 based on the filing. The issuer reports 159,391,229 shares outstanding.
The filer disclosed prior insider sales totaling 60,000 shares during the past three months (sales on 09/03/2025, 09/05/2025, 09/09/2025, and 10/02/2025) generating $3,724,770.00 in gross proceeds. The current notice states the securities were paid for in cash at acquisition and were granted by the issuer as RSUs.
Ionis Pharmaceuticals, Inc. filed a Form 144 notice reporting a proposed sale of 6,849 shares of common stock, with an aggregate market value of $472,718, to be executed approximately on 10/06/2025 through Stifel Nicolaus & Company on Nasdaq. The shares were acquired as Restricted Stock Units from the issuer on 01/15/2025 and paid for in cash on the same date. The filer reports total shares outstanding of 159,391,229. The notice also lists three prior sales by the same person, Eric Swayze, totaling 38,244 shares sold on 09/02/2025, 10/01/2025, and 10/02/2025, generating combined gross proceeds of $2,346,609. The signer affirms no undisclosed material adverse information and references Rule 10b5-1 conditions.
IONIS PHARMACEUTICALS, INC. (IONS) Rule 144 notice reports a proposed sale of 22,400 shares of common stock through Goldman Sachs & Co. LLC on 10/01/2025, with an aggregate market value of $1,473,920. The filing lists total shares outstanding of 159,391,229. The securities were acquired on multiple dates by the reporting party (option exercise and restricted stock units), including notable lots: 3,560 shares (09/16/2020), 6,394 shares (07/17/2018), 5,300 shares (02/14/2014) and 4,677 shares (07/15/2024). The filing also discloses related sales by the Joseph H. Wender Trust totaling 33,600 shares in Sep–Oct 2025 for gross proceeds of approximately $1.98 million. Other issuer identification fields are blank in the form content provided.